EDAP TMS S.A. — FY2015 Form 20-F
Business context and reporting period. This is an annual report for the fiscal year ended December 31, 2015, filed April 4, 2016; it does not provide standalone Q4 financial statements. EDAP develops and markets urological medical devices, principally HIFU systems for prostate tissue ablation and ESWL lithotripters for urinary stones. Financial statements are prepared under U.S. GAAP and reported in euros.
Financial performance and liquidity
| Metric | FY2015 | FY2014 |
|---|---|---|
| Total revenue | €32.253m | €26.785m |
| Net sales | €32.218m | €26.252m |
| Gross profit / margin | €13.785m / 42.8% | €11.201m / 42.7% |
| Operating income (loss) | €0.488m | (€1.736m) |
| Net income (loss) | (€1.667m) | (€0.512m) |
| Basic and diluted loss per share | (€0.07) | (€0.02) |
| Cash from operating activities | €1.338m | (€1.014m) |
| Cash and cash equivalents | €13.578m | €11.142m |
| Cash plus short-term investments | €14.578m | €12.142m |
| Total assets / shareholders’ equity | €38.581m / €14.430m | €32.154m / €15.141m |
Revenue rose 20.4%, primarily on higher UDS lithotripter sales. The UDS division generated €23.8m of net sales, up 31.6%; HIFU net sales were approximately €8.4m, slightly lower than 2014. UDS sold 52 devices versus 42; HIFU sold two Ablatherm units and five Focal One units, compared with four and six, respectively, in 2014. RPP treatment revenue and HIFU consumables, parts, leasing and services increased.
Operating expenses rose 2.8% to €13.3m. The return to operating profit reflected higher sales and gross profit, partly offset by selling and marketing expense growth. The net loss widened because net financial expense was €2.094m, including a €2.377m loss from fair-value changes in warrants; 2014 had €1.771m of net financial income, including a warrant fair-value gain. A €0.699m foreign-exchange gain and €0.759m income-tax expense also affected 2015 results.
Operating cash flow turned positive, while investing activities used €0.541m and financing activities generated €1.987m; year-end cash increased by €2.436m after a negative €0.347m exchange-rate effect. The filing says the €1.0m short-term investment was pledged as collateral for a €1.0m short-term loan. Current assets were €33.039m and current liabilities €16.271m. Short-term borrowings were €2.814m; conventional long-term debt was €0.802m, with €0.532m of capital-lease obligations. Separately, €4.377m of warrant liabilities was carried at fair value, including €4.205m non-current.
Material changes versus the prior period
- Revenue increased, with UDS machine sales the main driver; HIFU equipment sales declined and recurring RPP and service-related sales grew.
- Gross margin was broadly stable, while operating results improved from a €1.736m loss to €0.488m income.
- Despite the operating improvement, the net loss increased to €1.667m, mainly because warrant remeasurement shifted from a gain in 2014 to a significant loss in 2015.
- Operating cash flow improved by €2.352m to positive €1.338m. Cash and short-term investments increased by €2.436m, supported in part by financing inflows and warrant exercises.
Outlook, commentary and risks
- On November 9, 2015, EDAP received FDA 510(k) clearance to market Ablatherm Integrated Imaging HIFU in the U.S. for prostate tissue ablation. The clearance is not an approval for specific prostate-cancer treatment claims; further regulatory steps may be needed for those claims. Focal One was not approved for U.S. commercial distribution as of the filing.
- Management expected 2016 European R&D spending to remain around 10% of revenue and selling and marketing expense to increase significantly as the company expanded in the U.S. following Ablatherm clearance. No numerical revenue or earnings guidance was provided.
- The company reported a maximum €2.4m of potential non-dilutive Bpifrance funding over five years for the HECAM liver-cancer development project; €0.736m was received in June 2015, partly as a conditional subsidy.
- Management considered working capital sufficient for current requirements, but said additional capital might be needed for U.S. commercialization or development projects. Risks include reliance on HIFU adoption and reimbursement, regulatory and clinical uncertainty, intense competition, foreign-exchange exposure, seasonal and lumpy orders, and reliance on a single principal manufacturing site and certain single-source suppliers.
- Warrant liabilities are sensitive to share price and volatility and can create substantial non-cash earnings swings. The filing states that a 10% increase in the share price from year-end would raise warrant fair value by approximately €0.8m. Potential warrant and option issuance also presents dilution risk.
- The securities class action related to Ablatherm and FDA disclosures was dismissed; the appeal period ended without an appeal notice. A separate French tax dispute concerning repayment of historic state aid remained pending before the Conseil d’État.
- No dividends were paid for 2009–2015, and the company did not anticipate dividends for the foreseeable future.
Important facts for investors to verify
- Whether U.S. Ablatherm clearance translates into sustained device placements, procedure volumes and revenue, and what additional FDA authorization is required for treatment-specific claims.
- Whether positive operating cash flow is repeatable, given working-capital movements, seasonality and dependence on device orders.
- The composition and valuation sensitivity of the €4.377m warrant liability, as well as remaining warrant and option dilution exposure.
- Progress on HIFU reimbursement, physician adoption and Focal One regulatory plans, including the timing and cost of U.S. expansion.
- Debt maturities, collateral restrictions on cash investments, and funding needs for commercialization and development.
- The status and potential financial effect of the pending French tax appeal and any other contingencies.